Back to the future: multiagent chemotherapy in ovarian cancer revisited.
作者： Stephen A. Cannistra
DOI: 10.1200/JCO.1999.17.3.741
关键词: Laparotomy 、 Multiagent chemotherapy 、 Clinical trial 、 MEDLINE 、 Ovarian cancer 、 Oncology 、 Medicine 、 Internal medicine
摘要:
sci-hub.se 参考文章(12)
P G Rose, J A Blessing, A R Mayer, H D Homesley, Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology. ,vol. 16, pp. 405- 410 ,(1998) , 10.1200/JCO.1998.16.2.405
Virginie M.M. Herben, Vinodh R. Nannan Panday, Dick J. Richel, Jan H.M. Schellens, Nine van der Vange, Hilde Rosing, Fred D. Beusenberg, Solange Hearn, Edward Doyle, Jos H. Beijnen, Wim W. ten Bokkel Huinink, Phase I and Pharmacologic Study of the Combination of Paclitaxel, Cisplatin, and Topotecan Administered Intravenously Every 21 Days as First-Line Therapy in Patients With Advanced Ovarian Cancer Journal of Clinical Oncology. ,vol. 17, pp. 747- 747 ,(1999) , 10.1200/JCO.1999.17.3.747
S O'Reilly, G F Fleming, S D Barker, J R Walczak, M A Bookman, W P McGuire, R J Schilder, R D Alvarez, D K Armstrong, I R Horowitz, R F Ozols, E K Rowinsky, Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. Journal of Clinical Oncology. ,vol. 15, pp. 177- 186 ,(1997) , 10.1200/JCO.1997.15.1.177
G J Creemers, G Bolis, M Gore, G Scarfone, A J Lacave, J P Guastalla, R Despax, G Favalli, R Kreinberg, S Van Belle, I Hudson, J Verweij, W W Ten Bokkel Huinink, Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. Journal of Clinical Oncology. ,vol. 14, pp. 3056- 3061 ,(1996) , 10.1200/JCO.1996.14.12.3056
Stephen A. Cannistra, Cancer of the Ovary New England Journal of Medicine. ,vol. 329, pp. 1550- 1559 ,(1993) , 10.1056/NEJM199311183292108
W. J. Slichenmyer, E. K. Rowinsky, R. C. Donehower, S. H. Kaufmann, The Current Status of Camptothecin Analogues as Antitumor Agents Journal of the National Cancer Institute. ,vol. 85, pp. 271- 291 ,(1993) , 10.1093/JNCI/85.4.271
Lawrence Leichman, Norman Nigro, Vainutis K. Vaitkevicius, Basil Considine, Thomas Buroker, George Bradley, Horst G. Seydel, Steven Olchowski, Glenn Cummings, Cynthia Leichman, Laurence Baker, Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. The American Journal of Medicine. ,vol. 78, pp. 211- 215 ,(1985) , 10.1016/0002-9343(85)90428-0
F M Muggia, J D Hainsworth, S Jeffers, P Miller, S Groshen, M Tan, L Roman, B Uziely, L Muderspach, A Garcia, A Burnett, F A Greco, C P Morrow, L J Paradiso, L J Liang, Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Journal of Clinical Oncology. ,vol. 15, pp. 987- 993 ,(1997) , 10.1200/JCO.1997.15.3.987
J P Neijt, W W ten Bokkel Huinink, M E van der Burg, A T van Oosterom, P H Willemse, A P Heintz, M van Lent, J B Trimbos, J Bouma, J B Vermorken, Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. Journal of Clinical Oncology. ,vol. 5, pp. 1157- 1168 ,(1987) , 10.1200/JCO.1987.5.8.1157
J.B. Vermorken, A. Guechev, C.J.A. van Moorsel, G. Veerman, A.M. Bergman, G.J. Peters, P.E. Postmus, Combination chemotherapy studies with gemcitabine Seminars in Oncology. ,vol. 24, pp. 17- 23 ,(1997)